• Anixa Biosciences reported the first case of stable disease lasting three months in its Phase 1 ovarian cancer CAR-T trial.
• The result has already been observed in a patient treated in the highest-dose cohort evaluated so far.
• No dose-limiting toxicities have been seen to date, supporting continued dose escalation and further evaluation of early efficacy signals.
• Several treated patients have lived more than a year since therapy, including one beyond two years, suggesting potential durability worth monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050815PR_NEWS_USPR_____LA62990) on October 05, 2026, and is solely responsible for the information contained therein.